(lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
(lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1¨Crisk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.